An Investigation on a Novel Anti-tumor Fusion Peptide of FSH(33-53)-IIKK

A novel fusion peptide FSH(33-53)-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH(33-53)-IIKK was enhanced compared to that of IIKK only. FSH(33-53)-IIKK could in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Runlin, Liu, Ping, Pan, Donghui, zhang, Pengjun, Bai, Zhicheng, Xu, Yuping, Wang, Lizhen, Yan, Junjie, Yan, Yongjun, Liu, Xingdang, Yang, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910594/
https://www.ncbi.nlm.nih.gov/pubmed/27313792
http://dx.doi.org/10.7150/jca.14425
_version_ 1782438034408472576
author Yang, Runlin
Liu, Ping
Pan, Donghui
zhang, Pengjun
Bai, Zhicheng
Xu, Yuping
Wang, Lizhen
Yan, Junjie
Yan, Yongjun
Liu, Xingdang
Yang, Min
author_facet Yang, Runlin
Liu, Ping
Pan, Donghui
zhang, Pengjun
Bai, Zhicheng
Xu, Yuping
Wang, Lizhen
Yan, Junjie
Yan, Yongjun
Liu, Xingdang
Yang, Min
author_sort Yang, Runlin
collection PubMed
description A novel fusion peptide FSH(33-53)-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH(33-53)-IIKK was enhanced compared to that of IIKK only. FSH(33-53)-IIKK could inhibit the growth of tumor via apoptosis and autophagy pathways. In summary, combining the tumor marker-target peptide and anti-tumor peptide together may be an efficient way to search for better anti-tumor candidates.
format Online
Article
Text
id pubmed-4910594
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-49105942016-06-16 An Investigation on a Novel Anti-tumor Fusion Peptide of FSH(33-53)-IIKK Yang, Runlin Liu, Ping Pan, Donghui zhang, Pengjun Bai, Zhicheng Xu, Yuping Wang, Lizhen Yan, Junjie Yan, Yongjun Liu, Xingdang Yang, Min J Cancer Research Paper A novel fusion peptide FSH(33-53)-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH(33-53)-IIKK was enhanced compared to that of IIKK only. FSH(33-53)-IIKK could inhibit the growth of tumor via apoptosis and autophagy pathways. In summary, combining the tumor marker-target peptide and anti-tumor peptide together may be an efficient way to search for better anti-tumor candidates. Ivyspring International Publisher 2016-05-24 /pmc/articles/PMC4910594/ /pubmed/27313792 http://dx.doi.org/10.7150/jca.14425 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Research Paper
Yang, Runlin
Liu, Ping
Pan, Donghui
zhang, Pengjun
Bai, Zhicheng
Xu, Yuping
Wang, Lizhen
Yan, Junjie
Yan, Yongjun
Liu, Xingdang
Yang, Min
An Investigation on a Novel Anti-tumor Fusion Peptide of FSH(33-53)-IIKK
title An Investigation on a Novel Anti-tumor Fusion Peptide of FSH(33-53)-IIKK
title_full An Investigation on a Novel Anti-tumor Fusion Peptide of FSH(33-53)-IIKK
title_fullStr An Investigation on a Novel Anti-tumor Fusion Peptide of FSH(33-53)-IIKK
title_full_unstemmed An Investigation on a Novel Anti-tumor Fusion Peptide of FSH(33-53)-IIKK
title_short An Investigation on a Novel Anti-tumor Fusion Peptide of FSH(33-53)-IIKK
title_sort investigation on a novel anti-tumor fusion peptide of fsh(33-53)-iikk
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910594/
https://www.ncbi.nlm.nih.gov/pubmed/27313792
http://dx.doi.org/10.7150/jca.14425
work_keys_str_mv AT yangrunlin aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT liuping aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT pandonghui aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT zhangpengjun aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT baizhicheng aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT xuyuping aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT wanglizhen aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT yanjunjie aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT yanyongjun aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT liuxingdang aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT yangmin aninvestigationonanovelantitumorfusionpeptideoffsh3353iikk
AT yangrunlin investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT liuping investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT pandonghui investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT zhangpengjun investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT baizhicheng investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT xuyuping investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT wanglizhen investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT yanjunjie investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT yanyongjun investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT liuxingdang investigationonanovelantitumorfusionpeptideoffsh3353iikk
AT yangmin investigationonanovelantitumorfusionpeptideoffsh3353iikk

Ejemplares similares